Haiqing Ni

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Junjian Liu, H. Shen, Min Wu, 2021, Oncoimmunology.

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Bo Peng, Junjian Liu, Zhihai Wu, 2019, mAbs.

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy

Junjian Liu, Zhihui Kuang, Min Wu, 2020, Antibody therapeutics.

Structure of IgG-Fc hexamer reveals a mutual lock-and-key mode of Fc-Fc interaction

Xiaodong Xiao, Zhihai Wu, Bingliang Chen, 2022, bioRxiv.

Development and characterization of a novel anti-OX40 antibody for potent immune activation

Junjian Liu, Dongdong Wu, B. Prinz, 2020, Cancer Immunology, Immunotherapy.

IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.

Mengjia Zhu, Zhihui Kuang, Min Wu, 2022, Cancer letters.

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

Junjian Liu, Chenrong Huang, Yi-cong Bian, 2020, Cancer Immunology, Immunotherapy.

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

Junjian Liu, Ya-Wei Xiong, B. Prinz, 2021, Cancer Immunology, Immunotherapy.